Prime Medicine, Inc. (PRME)
$3.25-4.13%Close
SELLRECOVERY · day 11
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $587M
- Avg volume
- 3.0M
- Beta
- 2.31
- P/E (TTM)
- -2.95
- Short % float
- 59.16%
- Days to cover
- 12.9
- SI change
- +4.4%
- 1W
- +2.52%
- 1M
- +10.17%
- 3M
- +9.43%
- YTD
- -7.93%
- vs SPY 1W
- +3.71%
- vs SPY 1M
- +6.85%
- vs SPY 3M
- +7.04%
- vs SPY YTD
- -19.69%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- AVRBUYAnteris Technologies Global Corp.RECOVERYQ 31$8.80-2.00%
- NOTVSELLInotiv, Inc.CRISISQ -1$0.01+0.00%
- CATXBUYPerspective Therapeutics, Inc.RECOVERYQ 7$3.19-3.33%
- CLPTBUYClearPoint Neuro, Inc.RECOVERYQ 7$15.17-1.43%
- GELSSELLGelteq Limited Ordinary SharesCRISISQ -13$0.53-5.36%
- ACONBUYAclarion, Inc.RECOVERYQ -29$2.66-1.85%
- XNCRBUYXencor, Inc.BULLQ 17$29.00+4.32%
- RLAYBUYRelay Therapeutics, Inc.BULLQ 4$19.76+1.65%
- LEXXBUYLexaria Bioscience Corp.RECOVERYQ -8$10.54-3.48%
- ALTBUYAltimmune, Inc.RECOVERYQ -5$3.11+0.00%
- BMGLSELLBasel Medical Group Ltd Ordinary SharesCRISISQ -20$4.80-9.43%
- SLNBUYSilence Therapeutics plcRECOVERYQ 3$13.29+0.15%
Industry peers
FMP comparable companies · ranked by market cap
- MRVIBUYMaravai LifeSciences Holdings, Inc.$2.3BBULLQ -1$8.43-2.43%
- SEPNBUYSepterna Inc$1.8BCRISISQ 29$40.52+1.30%
- VIRBUYVir Biotechnology, Inc.$1.7BRECOVERYQ 12$9.91+1.33%
- TYRASELLTyra Biosciences, Inc.$1.6BCRISISQ 9$26.09+0.15%
- BCAXSELLBicara Therapeutics Inc. Common Stock$1.5BCRISISQ 0$23.58-1.34%
- REPLBUYReplimune Group, Inc.$1.2BRECOVERYQ 15$14.71-0.41%
- KURABUYKura Oncology, Inc.$1.1BRECOVERYQ 13$12.40+4.29%
- PROKSELLProKidney Corp.$541MRECOVERYQ 0$1.61+0.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 1
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-113.0%
REV YoY-
ROE-188.3%
EPS YoY-
ROA-75.4%
GROSS-1026
OP-4825
NET-4613
[VALUATION]
P/E TTM-2.95
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B14.47
P/FCF-
EV/EBITDA-3.61
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E282.54
ALTMAN Z-
CURR RATIO3.05
ND/EBITDA-
BETA2.31
